Alterations in the activity of the centrosomal kinase, Aurora-A/STK15, have been implicated in centrosome ampli®cation, genome instability and cellular transformation. How STK15 participates in all of these processes remains largely mysterious. The activity of STK15 is regulated by phosphorylation and ubiquitin-mediated degradation, and physically interacts with protein phosphatase 1 (PP1) and CDC20. However, the precise roles of these modi®cations and interactions have yet to be fully appreciated. Here we show that STK15 associates with a putative tumor and metastasis suppressor, NM23-H1. STK15 and NM23 were initially found to interact in yeast in a two-hybrid assay. Association of these proteins in human cells was con®rmed by co-immunoprecipitation from cell lysates and biochemical fractionation indicating that STK15 and NM23-H1 are present in a stable, physical complex. Notably, SKT15 and NM23 both localize to centrosomes throughout the cell cycle irrespective of the integrity of the microtubule network in normal human ®broblasts.
INTRODUCTION
Correct partitioning of the genome during mitosis depends upon the tightly regulated function of the mitotic spindle, which is composed of centrosomes, microtubules, molecular motors, chromosomes and kinetochores. The centrosome is the major microtubule-organizing center in mammalian cells and the counterpart to the spindle pole body of the yeast Saccharomyces cerevisiae. The centrosome in mammalian cells is composed of two perpendicularly positioned centrioles and the surrounding amorphous pericentriolar material. g-Tubulin and pericentrins are constitutive components of the centrosome, while other proteins, such as p53, pRB, BRCA1, BRCA2 and CDK2, accumulate at centrosomes in a cell cycle-dependent manner (1±4).
The centrosome normally duplicates once per cell cycle. This process is initiated during G 1 after cells pass the restriction point and is completed during G 2 . Centrosomes separate at G 2 /M, migrating to opposite poles of the cell to establish the microtubule network that is required to separate condensed chromosomes during M phase. Centrosomes play a vital role in establishing spindle bipolarity, in assembling spindle microtubules and in determining the plane of cytokinesis (for reviews see 5±10). More recently, accumulating evidence suggests a more direct role than had previously been appreciated for the centrosome in cytokinesis and cell cycle progression during the following G 1 and S phases (11±13).
Centrosome abnormalities, including morphological alterations, supernumerary centrosomes and acentriolar centrosomes, have been demonstrated in most human cancer cells, including those derived from breast, prostate, lung, colon and brain (for reviews see 14, 15 ; see also 2,16±18). Several oncogenes, tumor suppressor genes, cell division cycle and mitotic checkpoint genes are required for or involved in centrosome duplication, such as Ras, BRCA1 and BRCA2, CDK2, cyclin A and ATR (3,19±23) . Like other cellular processes, protein kinases play critical roles in the centrosome duplication process. Among the centrosomeassociated kinases, Aurora-A/AIK1/BTAK/STK15 kinase has been identi®ed as a candidate oncogene with connections to the centrosome cycle (24±27). Aurora-A/STK15 is overexpressed at both the mRNA and protein levels in a number of cancer cell lines, including breast, ovarian and prostate (25, 27) , and also in breast cancer tissues (28±30). Its kinase activity peaks at the G 2 /M phase of the cell cycle (25) . A mutant, kinase-inactive STK15 (Stk15 K162M) abolishes the oncogenic activity of STK15 in Rat1 ®broblasts, while a mutation conferring constitutive activation (Stk15 T288D) increases the kinase activity and enhances transforming potential (25) . These results strongly suggest that the kinase activity of STK15 is essential for STK15 function in vivo. STK15 is regulated by phosphorylation and ubiquitin-mediated degradation and interacts with CDC20 and protein phosphatase 1 (PP1) (31±35).
As a putative tumor suppressor, the nm23 gene was discovered on the basis of its reduced expression in highly metastatic cell lines (36) . Several studies have shown that NM23 overexpression can reduce the metastatic potential of melanoma and breast carcinoma cells in vivo (37±39). Furthermore, nm23 expression, at both the protein and mRNA levels, inversely correlates with high metastatic potential in numerous human cancers, including breast, gastric, cervical and ovarian carcinoma and melanoma (for a review see 40) .
The nm23 genes encode a protein family with eight subfamilies in human (41) . The well characterized biochemical activities of these proteins include NDP kinase (42) , protein histidine kinase, histidine-dependent protein phosphotransferase (43±45) and serine autophosphorylation (46, 47) . Data suggest that it is the level of autophosphorylation that correlates with tumor suppression by NM23 in melanoma cells (46) . NM23 associates with the cytoskeleton through an interaction with b-tubulin (48) . Awd, the¯y homolog of NM23, co-localizes with microtubules in Drosophila cells (49) and more recent data have indicated that NM23 may also be a component of the centrosome (50) .
Despite the strong evidence that STK15/Aurora-A/BTAK regulates centrosome duplication, cellular transformation and aneuploidy, little evidence directly connects this kinase with known oncogenes or tumor suppressors. Here we provide the data that STK15 interacts with the tumor suppressor NM23, both in yeast and in normal human ®broblasts. NM23 and STK15 co-fractionate in a high molecular weight complex and co-localize at centrosomes throughout the cell cycle.
MATERIALS AND METHODS

Plasmids and primers
Full-length STK15 was obtained by PCR from plasmid pcDNA3-STK15/BTAK (a kind gift from Dr S. Sen; 27) using the primers STK15-CHIS5 (CGGGATCCCGG-GGATGGACCGATCTAAAGAAACTGC) and STK15-3XhoI (CCGCTCGAGCTAAGACTGTTTGCTAGCTGA-TTC). STK15-GBT8 was constructed by cloning into the BamHI and XhoI sites of pGBT8. A HeLa cDNA two-hybrid library was used in the two-hybrid screen (51) . Full-length nm23-H1 cDNA was obtained by PCR of EST clones ordered from Genome Systems Inc. (EST clones 590228 and 3454119) using the primers NM23GAD-5EcoRI (CGGAATTCCA-TGGCCAACTGTGA-GCG) and NM23-3XhoI (CCGCTC-GAGTCATTCATAGATCCAG). pGADGH-NM23-H1 was constructed by cloning the the PCR product into the EcoRI and XhoI sites of pGADGH (51) .
Cell culture
Human IMR90 cells were purchased from ATCC (CCL-186). These were immortalized by infection with a hTERT retrovirus at passage 25 (52) . The cells were cultured at 37°C in a 5% CO 2 incubator in Dulbecco's modi®ed medium (DMEM) supplemented with 10% (v/v) heat-inactivated fetal bovine serum (FBS), 10% (v/v) non-essential amino acids (NEAA) and penicillin/streptomycin (100 IU/ml and 100 mg/ml, respectively). Nocodazole treatment was done by addition of 10 mg/ml nocodazole to the culture medium followed by incubation for 10 min at 37°C.
Two-hybrid screening
To identify proteins interacting with STK15, we screened a plasmid library of fusions between the GAL4 activation domain (GAD, residues 768±881) and HeLa cell cDNA fragments. The Gal4 DNA-binding domain (GBD) is fused with STK15 in the pSTK15-GBT8 construct. The screen was done in a S.cerevisiae reporter strain (pJ64-4a, W303MATa trp9-901, 112 ura3-52 his3-200 gal4 gal80 GAL2-ADE2 LYS2::GAL1-HIS3 met2::GAL7-LacZ, a kind gift from R. Rothstein). A total of 1.2 Q 10 6 transformants were assayed on synthetic drop-out medium (without leucine, histidine and tryptophan, SC ±HLW) plates. A total of 104 colonies turned blue on X-gal plates, and the plasmids were recovered from 54 colonies. Retransformation of the plasmids into the test strain con®rmed that 20 plasmids retained the ability to activate the b-galactosidase reporter. Sequencing analysis revealed four plasmids contained coding sequences from nm23-H1 genes. The four plasmids were derived from two independent cDNAs comprising nucleotides 25±330 and 4±159 of the nm23-H1 coding region.
Antibodies
A polyclonal antiserum against STK15 (anti-STK15) was raised in rabbits by presenting a KLH-conjugated nine amino acid peptide (synthesized by Research Genetics, Huntsville, AL) from the C-terminus of STK15 (NKESASKQS). The serum was af®nity puri®ed using a resin prepared from the synthesized peptide (53) . The antibody recognizes a 46 kDa band in whole cell lysates. For some studies, the af®nity- Immunoblotting, immunoprecipitation and¯uorescence microscopy IMR90 cells were lysed in IP buffer [125 mM NaCl, 1 mM Mg(OAc) 2 , 1 mM CaCl 2 , 5 mM EGTA, 20 mM HEPES (pH 7.6), 1% (v/v) NP-40, with freshly dissolved 2 mM DTT, 0.2 mM phenylmethylsulfonyl¯uoride and protease inhibitors (Roche, Mannheim, Germany)] on ice for 10±15 min. Protein concentrations were determined by Bradford assay (Bio-Rad). A total of 10±50 mg protein was analyzed by 10 or 12% (v/v) SDS±PAGE (54) .
Immunoprecipitation was performed as described (55) with the following modi®cations. IMR90 cells were lysed in IP buffer at 4°C for 10 min. The cell lysate was cleared by centrifugation at 10 000 g for 10 min at 4°C. The supernatant was pre-cleared by incubation for 30 min with agarose±protein A or agarose±protein G beads (Pierce). The supernatant was further incubated with 5 mg antibodies for 3±4 h at 4°C with agitation, after which agarose±protein A or A/G mixture (pre-blocked by incubation with 5% BSA) was added for 1 h at 4°C. The beads were then washed three times with IP buffer. For release of STK15 and associated proteins, beads were incubated with 1 mg/ml synthetic antigen in phosphate-buffered saline (PBS) for 1 h at 4°C with agitation. The dialyzed eluate was then loaded onto Mono Q and was eluted with a linear gradient from 0 to 1000 mM potassium chloride in MonoQ buffer. The peak fractions for STK15 (from 350 to 450 mM) were collected and pooled before 0.5 ml was loaded onto Superose 6. The column was run at 0.4 ml/min with Super6 buffer [20 mM HEPES (pH 7.6), 10% (v/v) glycerol, 1 mM DTT, 1 mM EDTA, 0.01% NP40 and 300 mM NaCl]. Fractions of 1 ml were collected and proteins were precipitated with TCA. The pellets were then re-dissolved in 0.1 N NaOH and loaded onto SDS±PAGE gels for immunoblot analysis.
RESULTS AND DISCUSSION
NM23 and STK15 interact
To search for proteins that interact with STK15 we conducted a yeast two-hybrid screen using the full-length STK15 coding sequence as a bait (see Materials and Methods). Among the positives, we found four plasmids containing the human nm23-H1 coding sequence. Two different fusions were represented, which cover a common N-terminal region of NM23-H1 (three represented fusions of Gal4 to amino acids 9±110, and another represented amino acids 2±53). This suggests that the region of NM23-H1 between amino acids 2 and 53 binds directly to STK15. We inserted the full-length nm23-H1 coding sequence into pGADGH (pGADGH-NM23-H1) and con®rmed that this fusion protein also interacts speci®cally with STK15 (Fig. 1) . Only in combination with STK15 did colonies carrying NM23-H1 show signi®cant b-galactosidase expression. Neither NM23-H1 alone nor NM23 combined with other Gal4 fusion proteins (e.g. ras) induced b-galactosidase expression. However, at least in yeast, the degree of X-gal staining indicated that the interaction between STK15 and Nm-23H1 was relatively weak, as compared to the positive control (pGBT8-Ras and pGADGH-Raf in this case). It was therefore essential to investigate whether these proteins physically interacted in mammalian cells.
To test whether STK15 and NM23 also interact in vivo in human cells, proteins were immunoprecipitated from IMR90 cell lysates using anti-STK15 and anti-NM23 antibodies (see Materials and Methods). The presence of NM23 and STK15 in the precipitate was examined by western blotting (Fig. 2) . Anti-STK15 speci®cally co-immunoprecipitates STK15 and NM23. Pre-incubation of the STK15 antibody with its cognate synthetic antigen coordinately abolished immunoprecipitation of both STK15 and NM23 (Fig. 2, lanes 1 and 2) . The NM23 antiserum also immunoprecipitated NM23 and STK15, while normal mouse IgG did not bring down signi®cant amounts of either NM23 or STK15 (Fig. 2, lanes 3 and 4) . We did detect some non-speci®c binding of NM23 to protein A/G beads; however, this is not unexpected considering that NM23 is a relatively abundant protein (lane 3). The foregoing results indicate that STK15 and NM23 associate with each other in human cells. Comparing the total amount of NM23 present in the cell and the amount precipitated by anti-NM23-H1 antibody (Fig. 2, lane 4 , and western data not shown) to the amount of NM23 immunoprecipitated by the STK15 antibody (Fig. 2 , lane 2; both lanes 2 and 4 were from the same amount of cell lysate) suggests that a relatively small percentage of NM23-H1 exists in a stable, physical complex with STK15. In western blots of the anti-STK15 immunoprecipitations, we also detected another protein of~54 kDa, in addition to the 46 kDa protein that is predicted to be an STK15 protein derived from an alternatively spliced mRNA. We have not de®nitively determined the identity of the 54 kDa protein; however, the human genome sequencing project has predicted an alternatively spliced STK15 transcript that is predicted to generate a protein of this size (accession no. XP_009546). In contrast, we have con®rmed that the~46 kDa band is STK15 by MALDI-TOF mass spectrometry.
To verify the interaction between STK15 and NM23-H1, protein extracts from IMR90 cells were fractionated by FPLC. Throughout the puri®cation, we followed STK15 by western blotting. Western analysis of the puri®cation through Mono S, Mono Q and Superose 6 columns revealed that STK15 is present in two distinct forms, a high molecular weight protein complex (Fig. 3, fractions 10 and 11,~2 MDa) and a relatively low molecular weight complex (fractions 15±17,~350 KDa). NM23-H1 also shows a peak around fractions 15±17, which exactly co-migrates with STK15 in the~350 kDa complex (Fig. 3) . This result supports the notion that STK15 and NM23 coexist in a protein complex in vivo.
STK15 and NM23 co-localize at centrosomes
It has been shown that STK15 localizes to centrosomes in mitotic cells (25) (Fig. 4A) . By ®xing IMR90 cells in 0.5% (w/v) formaldehyde, we can also detect STK15 at centrosomes during interphase in immortalized human IMR90 cells. Centrosomes were visualized by simultaneous staining with an anti-centrin2 antiserum, which locates the two centrioles in the centrosome (Fig. 4) . The amount of STK15 at centrosomes increases as cells move from interphase to prophase, and SKT15 also becomes apparent on the mitotic spindle. These results suggest that STK15 is a centrosome component throughout the cell cycle (Fig. 4A ), but becomes enriched at centrosomes during mitosis. NM23-H1 also localizes to centrosomes in interphase cells (Fig. 4B) (50) . At the beginning of prophase NM23-H1 accumulates at the centrosome, as judged from the increased intensity of staining (Fig. 4B, prometaphase) (50) . The association of NM23 with centrosomes persists through the mitotic phase and NM23-H1 also distributes somewhat to the microtubule spindles adjacent to the centrosome from metaphase to telophase (Fig. 4B) (50) . From late telophase to cytokinesis, NM23-H1 also accumulates at the newly forming midbody microtubules (Figs 4C and 5C in late telophase and cytokinesis cells). Interestingly, an identical distribution pattern at the midbody microtubules is also observed for STK15 (Figs 4C and 5B in late telophase and cytokinesis cells). The accumulation of NM23-H1 on centrosomes coincides with the enrichment of STK15 at the centrosome and with increased STK15 kinase activity at the beginning of mitosis (25) .
In order to test whether STK15 and NM23 co-localize, we simultaneously labeled IMR90 cells with b-tubulin-FITC, NM23-TRITC and STK15-AF647 (Cy5) and visualized the localization of each protein (Fig. 4C) . b-Tubulin immunouorescence reveals interphase microtubule ®laments and centrosomes. In mitotic phase, b-tubulin localizes both to the mitotic spindles and to the centrosomes (Fig. 4C ). NM23 and STK15¯uorescence is present together at the centrosome at all cell cycle phases (Fig. 4C , the right side merged lane). These results con®rm that STK15 and at least some fraction of NM23 co-localize to centrosomes throughout the cell cycle.
STK15 and NM23 centrosomal localization is microtubule-independent
There is some evidence indicating that NM23-H1 is b-tubulin associated and localized through g-tubulin to centrosomes (48, 50) . In order to clarify that STK15 and NM23 do not associate indirectly at centrosomes through their separate interactions with microtubules, we treated IMR90 cells with nocodazole (see Materials and Methods), which rapidly dissipates the microtubule network in cells (Fig. 5B and C,  b-tubulin column) .
There are several centrosome-associated proteins that localize to this structure in a spindle-dependent fashion. Of these, perhaps the most well studied is g-tubulin (56) . Upon nocodazole treatment of mammalian cells, centrosomal g-tubulin is reduced by~2-fold in interphase cells and by at least 4-fold in mitotic cells (56) . Using b-and g-tubulin antisera, we con®rmed that our nocodazole treatment dissipates the microtubule network and dramatically reduces the amount of g-tubulin associated with the centrosome (Fig. 5A±C) . In such cells, STK15 and NM23-H1 still localize to the centrosome with the same pattern and intensity of staining seen in untreated cells (Fig. 5B and C) . The result suggests that the interaction between STK15 and NM23 and their centrosome localization are microtubule-independent.
A previous study (57) showed that the centrosomal localization of a Xenopus laevis homolog of STK15, Aurora-A, is microtubule-dependent. This result was obtained using a construct consisting of the only N-terminal domain of Aurora-A (57). However, microtubule-independent localization of Aurora-A to the centrosome was observed using a fulllength Aurora-A construct (57) . Here, we also observed that the localization of full-length STK15 to the centrosome is not dependent on microtubules (Fig. 5B) .
A previous study showed that STK15 associates with centrosomes only at onset of mitosis (25) . However, our immuno¯uorescence studies indicate that STK15 associates with centrosomes throughout the cell cycle. This discrepancy could arise because of the different cell types used in these studies. Here we examined STK15 in normal or immortalized human ®broblasts cells while previous studies have used human cancer cells and rodent ®broblast cells. Furthermore, different antisera and ®xation conditions were used in this and in previous studies. We do, however, observe an increase in the abundance of STK15 at centrosomes in mitotic cells.
STK15 is a centrosome-associated kinase, overexpression of which in rodent or human cancer cells causes improper centrosome duplication, aneuploidy and cellular transformation (25, 27) . The abundance of STK15 is controlled by the ubiquitin pathway (32, 33) and has been linked to CDC20, an APC activator (31) . STK15 kinase activity is also controlled by PP1, a protein phosphatase (34) . Here we provide evidence that STK15 is associated with a putative tumor and metastasis suppressor protein, NM23-H1. These proteins physically interact and co-localize to centrosomes throughout the cell cycle in human IMR90 cells. NM23-H1 plays important roles in cell proliferation, differentiation, tumorigenesis and metastasis.
The interaction between NM23 and STK15 might potentially modulate either of their activities through a number of mechanisms, ranging from allosteric regulation to induced localization to enzymatic modi®cation. We tested the latter possibility using STK15 and NM23-H1, puri®ed from Escherichia coli. Puri®ed STK15 was enzymatically active, as judged by its ability to phosporylate a model substrate, MBP. NM23 also displayed activity as judged by autophosphorylation and NDP kinase activities (data not shown; 46, 58) . Neither of the puri®ed proteins was capable of chemically modifying the other nor did mixing these proteins affect their activities towards model substrates in vitro. Therefore, the exact nature of the functional relationship between NM23 and SKT15 remains unknown. 
